Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
aTyr Pharma Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
LIFE
Nasdaq
8731
https://www.atyrpharma.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for aTyr Pharma Inc
aTyr Pharma to Participate in April Investor Conferences
- Apr 1st, 2024 12:00 pm
3 Penny Stocks That Could Be Multibaggers in the Making: March Edition
- Mar 26th, 2024 6:19 pm
aTyr Pharma Full Year 2023 Earnings: Revenues Disappoint
- Mar 16th, 2024 12:56 pm
aTyr Pharma, Inc. (NASDAQ:LIFE) Q4 2023 Earnings Call Transcript
- Mar 15th, 2024 5:33 pm
Q4 2023 aTyr Pharma Inc Earnings Call
- Mar 15th, 2024 3:30 pm
aTyr Pharma Inc (LIFE) Reports Full Year 2023 Financial Results and Corporate Progress
- Mar 15th, 2024 3:01 pm
aTyr Pharma Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate Update
- Mar 14th, 2024 8:00 pm
aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2023 Financial Results
- Feb 28th, 2024 1:00 pm
We Think aTyr Pharma (NASDAQ:LIFE) Can Afford To Drive Business Growth
- Feb 23rd, 2024 6:28 pm
aTyr Pharma Announces Expanded Access Program (EAP) for EFZO-FITâ„¢ Clinical Trial Participants
- Feb 21st, 2024 1:00 pm
After losing 23% in the past year, aTyr Pharma, Inc. (NASDAQ:LIFE) institutional owners must be relieved by the recent gain
- Feb 3rd, 2024 12:16 pm
aTyr Pharma to Present Posters Highlighting Importance of Neuropilin-2 in Immune Regulation at Keystone Symposia on Myeloid Cell Diversity
- Jan 29th, 2024 1:00 pm
aTyr Pharma Announces Howard University President Emeritus Dr. Wayne A. I. Frederick as Advisor
- Jan 18th, 2024 1:00 pm
aTyr Pharma's Market Cap Drops To US$66m Leaving Insiders With Losses
- Nov 13th, 2023 2:27 pm
aTyr Pharma Presents Poster Demonstrating Preclinical Effects of Efzofitimod in Rheumatoid Arthritis and Rheumatoid Arthritis-Associated ILD at the ACR Convergence 2023
- Nov 13th, 2023 1:00 pm
aTyr Pharma Announces Third Quarter 2023 Results and Provides Corporate Update
- Nov 9th, 2023 9:00 pm
aTyr Pharma to Present at November Investor Conferences
- Nov 1st, 2023 12:00 pm
aTyr Pharma Announces Dosing of First Patient in Phase 2 EFZO-CONNECTâ„¢ Study of Efzofitimod in Patients with SSc-ILD
- Oct 31st, 2023 12:00 pm
Down -9.64% in 4 Weeks, Here's Why You Should You Buy the Dip in Atyr Pharma (LIFE)
- Aug 30th, 2023 1:35 pm
We're Hopeful That aTyr Pharma (NASDAQ:LIFE) Will Use Its Cash Wisely
- Aug 30th, 2023 11:15 am
Scroll